Inventiva S.A.

Paris Stock Exchange IVA.PA

Inventiva S.A. Price to Sales Ratio (P/S) on January 14, 2025: 11.33

Inventiva S.A. Price to Sales Ratio (P/S) is 11.33 on January 14, 2025, a -32.71% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Inventiva S.A. 52-week high Price to Sales Ratio (P/S) is 17.46 on March 18, 2024, which is 54.07% above the current Price to Sales Ratio (P/S).
Inventiva S.A. 52-week low Price to Sales Ratio (P/S) is 7.08 on October 09, 2024, which is -37.55% below the current Price to Sales Ratio (P/S).
Inventiva S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 12.60.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Paris Stock Exchange: IVA.PA

Inventiva S.A.

CEO	Mr. Frederic Cren
IPO Date	Feb. 15, 2017
Location	France
Headquarters	50 rue de Dijon
Employees	123
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Key trends

Past 5 years